eligibility_summary
Include: 18-65, biopsy-proven unresectable/metastatic solid tumor, no prior systemic therapy for metastasis (>=6 mo since neo/adjuvant), measurable (RECIST 1.1), ECOG 0-1, adequate organ function, not pregnant/using contraception. Exclude: recent RT/surgery/other trials, mirabegron allergy, active cancer, brain mets, uncontrolled HTN, recent bleeding/thrombosis/anticoagulation, heart disease/LVEF<50, autoimmune disease, live vaccine, active TB/HIV/hepatitis, severe renal failure/dialysis.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Interventions: Mirabegron (aka milaberon/mirabeeron), an oral small‑molecule β3‑adrenergic receptor agonist, added to standard regimens: anti‑PD‑1 mAbs (sintilimab, tislelizumab, serplulimab, camrelizumab), bevacizumab (anti‑VEGF mAb), cetuximab (anti‑EGFR mAb), rituximab (anti‑CD20 mAb), plus chemotherapies (platinums, 5‑FU/capecitabine, oxaliplatin, gemcitabine, taxanes, etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone). Mechanisms: Mirabegron activates β3‑AR on adipocytes/brown fat, inducing browning and UCP1‑mediated thermogenesis, reprogramming systemic/TME lipid metabolism with potential anticancer effects, PD‑1 blockade reinvigorates T cells, VEGF blockade inhibits angiogenesis, EGFR blockade inhibits signaling and mediates ADCC, CD20 mAb depletes B cells, cytotoxics disrupt DNA synthesis/crosslinking, topoisomerase II, and microtubules. Targets: adipocytes/BAT (β3‑AR/UCP1), T cells (PD‑1), endothelial cells (VEGF), tumor EGFR, B cells (CD20), proliferating tumor cells.